학술논문
Corrigendum to “The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2021;100:225–237 (Kidney International (2021) 100(1) (225–237), (S0085253820314186), (10.1016/j.kint.2020.10.046))
Document Type
Erratum
Author
Ariceta, G.; Dixon, B.P.; Kim, S.H.; Kapur, G.; Mauch, T.; Ortiz, S.; Vallee, M.; Denker, A.E.; Kang, H.G.; Greenbaum, L.A.; Lovell, H.; Muff-Luett, M.; Malone, K.; Adeagbo, O.; Wilkerson, A.; Fraga, G.; Sarri, S.; Cheong, H.I.; Ahn, Y.H.; Han, K.H.; Wühl, E.; Ardissino, G.; Capone, V.; Constantinescu, A.; Boydstun, I.; Raafat, R.; Mersha, M.; Wandique-Rapalo, B.; Hataya, H.; Hamada; Terano; Rees, L.; Pose, A.G.; Pérez, I.V.; Vilariño, M.C.; Adams, B.; Nathalie, T.
Source
In: Kidney International . (Kidney International, July 2023, 104(1):205)
Subject
Language
English
ISSN
15231755
00852538
00852538